AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye

Dry Eye Clinical Trial

— AST/SS  

Official title:

Autologous Serum Tears Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With Sjögren's Syndrome Dry Eye

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06013436
• Other study ID #: 22LLZX10
• Status: Completed
• Start date: June 1, 2022
• Est. completion date: June 1, 2023

Study information

• Verified date: August 2023
• Source: Chengdu University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of the present study was to evaluate the efficacy of autologous serum tears combined with 0.05% cyclosporin eye drop in treating Sjögren's syndrome dry eye and their effect on corneal nerves. We assessed the impact of 12-week AST combined with 0.05% cyclosporin eye drop treatment on signs, symptoms, and sub-basal nerve density (SND) in patients with dry eyes related to Sjogren's syndrome.

Description:

Objective: To describe the clinical efficacy and safety of the treatment of Sjögren's syndrome dry eye using autologous serum tears combined with 0.05% cyclosporin eye drop and to evaluate their effect on corneal nerves. Design: Singal-center, prospective, observational study. Patients and methods: Thirty eyes of fifteen patients with dry eye related to Sjögren syndrome were enrolled in this study. Following a 4-week washout period, the treatment was inverted for each patient for the same duration and treatment. Ocular Surface Disease Index (OSDI), tear film, break-up time, corneal staining with the use of fluorescein, Schirmer's test and corneal confocal microscopy were investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients were diagnosed with SS according to the classification criteria defined by the American-European Consensus Group for the diagnosis of SS and also diagnosed with severe DED based on the consensus of Chinese dry eye experts.
• Age 18-65 years old.
• Controlled collagen disease by the same rheumatologists at least 3 months prior to the initiation of the trial.
• At least one eye that failed to respond to previous treatments including lartificial tears, topical ocular NSAIDs or corticosteroids.

Exclusion Criteria:

• Patients with DED related to meibomian gland dysfunction, blepharitis, abnormal blinking, conjunctival relaxation or any other diseases besides SS.
• Diagnosed with allergic conjunctivitis, uveitis, ocular hypertension, retinopathy and other eye diseases.
• Those who have a history of previous ocular oprations, eye injuries or contact lenses usage.
• Known hypersensitivity to experimental drugs or any of its ingredients.
• Necessity to modify the systemic treatment of previous diseases during the trial.
• Pregnancy or lactation.
• Severe systemic disease.

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Ocular Surface Disease
• Sjogren's Syndrome
• Syndrome

Intervention

Drug:
• Autologous serum tears combined with 0.05% cyclosporin eye drop
All patients administrated autologous serum tears twelve times daily(per hour) and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.

Locations

Country	Name	City	State
China	Hospital of Chengdu University of Traditional Chinese Medicine	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Chengdu University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cornea nerves	cornea sub-basal nerve density	12 weeks
Primary	cornea staining score	to evaluate corneal epithelial repair(0= no staining; 1= less than 5 staining points; 2= more than 5 and less than 30 staining points within the range of two quadrants; and 3= staining exceeding two quadrants or staining points more than 30)	4 weeks
Secondary	Ocular Surface Disease Index (OSDI)	to assess the quality of life and clinical symptom;The survey generated a score ranging 0-100 (0 indicated absence of eye discomfort and 100 represented maximum eye discomfort)	4 weeks
Secondary	Schirmer's test	to assess tear flow	4 weeks
Secondary	tear film breakup time (TBUT)	to assess tear film stability	4 weeks